Abstract:Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. The majority of patients can be cured under the treatment of R-CHOP, but one third of patients will relapse and have a worse prognosis. To exploring a biomarker which can predict clinical behavior may aid in the implementation of novel therapeutic strategies. Inhibitor of DNA-binding 3 (ID3) is a helix loop-helix transcription factor, which negatively regulates the cell proliferation. ID3 mutations occur in 34-68% of Bukitt's lymphoma (BL) and are assiociated with lymphomagenesis. A variety of nonsense and frameshift mutations in ID3 as well as missense mutations in the region encoding the HLH domain reduces or eliminates ID3 protein function in BL. ID3 mutation is rare in DLBCL. The prognostic value of ID3 protein level remains unclear in DLBCL. Therefore, we conducted a retrospective study to investigate the impact of ID3 expression in DLBCL patients. Methods: One hundred DLBCL patients treated at Fudan University Shanghai Cancer Center with available diagnostic biopsy material were identified. ID3 expression was determined and quantified by immunohistochemistry (IHC) with staining intensity and percentage of positive cells (IRS). The IRS cut off value for ID3 positive is equal or more than 6. Kaplan-Meier and life table method were used to calculate progression free survival (PFS) and overall survival (OS). Curves were compared with the long-rank test in both groups. Correlation between the ID3 expression and clinical variables were tested by Pearson Chi Square test and a two-sided P value of <0.05 was considered to be statistically significant. Result: Seventy-seven (77%) of patients was overexpressed ID3 and 23% patients was shown ID3 negative. Among these pateints, ID3 positive patients had a trend of better outcome without a significance. The PFS and OS were 65% and 68% in ID3 negative group; 80% and 85% in ID3 positive group, respectively. According to cell of origin, the ID3 deficiency were 24% (10/41) in GCB patients and 22% (13/59) in non-GCB patients (p=0.82). the ID3 overexpression was associated with a better OS compared with ID3 negative patients in non-germinal center B-cell lymphoma group (non-GCB) (85% vs 46%, p=0.047). Although the PFS of ID3 positive patients was better than negative group (77% vs 59%, p=0.256), there was no significance. In GCB patients, there was no differences between the ID3 positive group and negative groups in terms of PFS or OS. The basic characteristics were no difference between ID3 positive and negative groups. Conclusion: This is the first report demonstrating that ID3 overexpression is a positive predictor of clinical outcome in non-GCB lymphoma patients. ID3 is a potential novel target to treat lymphoma and further investigation of ID3 need to be done in the near future. (Research supported by National Natural Science Foundation of China (no.81670177, no.81001048) Figure Disclosures No relevant conflicts of interest to declare.

JMJD3 promotes survival of diffuse large B-cell lymphoma subtypes via distinct mechanisms

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B cell subtype of diffuse large B cell lymphoma and demonstrates high risk gene expression …

MYC/BCL2 Protein Coexpression Contributes to the Inferior Survival of Activated B-cell Subtype of Diffuse Large B-cell Lymphoma and Demonstrates High-Risk Gene Expression Signatures: a Report from the International DLBCL Rituximab-CHOP Consortium Program.

Dysregulated CXCR4 Expression Promotes Lymphoma Cell Survival and Independently Predicts Disease Progression in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma.

MYC/BCL2 Protein Co-Expression Defines a Unique Subset of Aggressive Lymphoma and Contributes to the Inferior Prognosis of Activated B-cell Subtype of Diffuse Large B-cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program Study

JMJD3 Facilitates C/EBPβ-centered Transcriptional Program to Exert Oncorepressor Activity in AML

Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma

JAM-A Overexpression is Related to Disease Progression in Diffuse Large B-cell Lymphoma and Downregulated by Lenalidomide

JMJD3 participates in activation and apoptosis of IFN-αand TLR7-induced B cells

Jq1, A Selective Bromodomain Inhibitor, Augment The Immunogenicity Of Mantle Cell Lymphoma By Influencing The Expression Of Pd-L1

Jmjd1c demethylates STAT3 to restrain plasma cell differentiation and rheumatoid arthritis

Inhibitor of DNA Binding 3 Is a Potential Prognostic Biomarker in Non-GCB Diffuse Large B-Cell Lymphoma

Aberrant expression of JMJD3 in SLE promotes B-cell differentiation.

B-cell Receptor-Mediated NFATc1 Activation Induces IL-10/STAT3/PD-L1 Signaling in Diffuse Large B-cell Lymphoma

JMJD3 Enhances Invasiveness and Migratory Capacity of Non-Small Cell Lung Cancer Cell Via Activating EMT Signaling Pathway.

JMJD1C forms condensates to facilitate a RUNX1-dependent gene expression program shared by multiple types of AML cells

Specific TCR V–J gene segment recombinations leading to the identification pan-V–J CDR3s associated with survival distinctions: diffuse large B-cell lymphoma

Jun-regulated Genes Promote Interaction of Diffuse Large B-cell Lymphoma with the Microenvironment.

Integrated multi-omics profiling reveals the ZZZ3/CD70 axis is a super-enhancer-driven regulator of diffuse large B-cell lymphoma cell-natural killer cell interactions

JMJD3 Regulates CD4+ T Cell Trafficking by Targeting Actin Cytoskeleton Regulatory Gene Pdlim4

JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors